Two Novel Product Platforms

FLAG Therapeutics, Inc. is an early-stage oncology company focused on the development of therapies based on two investigational product platforms:

  • Anti-angiogenic/Anti-tubulin (AA/AT) Compounds:  Small water-soluble dual-acting molecules designed to harness the power of two well-understood anti-cancer activities into one molecular function.  These molecules shut off the blood supply to tumors and effectively (and safely) kills the weakened tumors.  Several molecules are small enough (MW under 300) to efectively penetrate the blood brain barrier (BBB).
    • Brain Cancer (GBM)
    • Triple Negative Breast Cancer (TNBC)
       
  • Facilitated Transporter Anti-cancer (FTAC) Compounds:  Small molecule drugs designed to specifically target cancer cells (any bypass normal cells) and destroy tumor cells either via GARFTase or SHMT-2 inhibition.
    • Mesothelioma
    • Pancreatic Cancer

Latest News

  • FLAG Therapeutics issued US patent 9,987,283 on June 5, 2018
    • Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof

Upcoming Presentations